PRESS RELEASE

from Bio-Rad Laboratories GmbH (isin : DE0007165607)

SARTORIUS AG: Resolutions of the Annual General Meeting of Sartorius AG

EQS-News: SARTORIUS AG / Key word(s): AGM/EGM
SARTORIUS AG: Resolutions of the Annual General Meeting of Sartorius AG

29.03.2023 / 17:04 CET/CEST
The issuer is solely responsible for the content of this announcement.


Göttingen, March 29, 2023

Resolutions of the Annual General Meeting of Sartorius AG

At today’s virtual Annual General Meeting, the shareholders of Sartorius AG approved the proposals of the Executive Board and the Supervisory Board by a large majority, including the proposal to distribute a dividend of 1.44 euros per preference share and 1.43 euros per ordinary share. The total amount disbursed will be 98.2 million euros. In the previous year, dividends were 1.26 euros per preference share and 1.25 euros per ordinary share.

This press release contains forward-looking statements about the future development of the Sartorius Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius assumes no liability for updating such statements in light of new information or future events. This is a translation of the original German-language release. Sartorius shall not assume any liability for the correctness of this translation. The original German release is the legally binding version.


Further information
www.sartorius.com/shareholders-meeting
Image files


Financial calendar
April 20, 2023: Publication of first-quarter figures (January to March 2023)
July 21, 2023: Publication of first-half figures (January to June 2023)
October 19, 2023: Publication of nine-month figures (January to September 2023)


A profile of Sartorius
The Sartorius Group is a leading international partner of life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications and vaccines safely, rapidly and economically. The company based in Goettingen, Germany, has a strong global reach with around 60 production and sales sites worldwide. Sartorius delivers significant organic growth and regularly expands its portfolio through the acquisition of complementary technologies. In fiscal 2022, the company generated sales revenue of around 4.2 billion euros. At the end of 2022, around 16,000 employees were working for customers around the globe.


Contact
Timo Lindemann
Corporate Communications
+49 (0)551 308 4724
timo.lindemann@sartorius.com

Follow Sartorius on Twitter @Sartorius_Group and on LinkedIn.


29.03.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language:English
Company:SARTORIUS AG
Otto-Brenner-Straße 20
37079 Göttingen
Germany
Phone:+49.(0)551-308.0
Fax:+49.(0)551-308.3289
E-mail:info@sartorius.com
Internet:www.sartorius.com
ISIN:DE0007165607, DE0007165631
WKN:716560 , 716563
Indices:DAX, TecDAX
Listed:Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID:1589605

 
End of NewsEQS News Service

1589605  29.03.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1589605&application_name=news&site_id=symex
See all Bio-Rad Laboratories GmbH news